Evercore ISI Group Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Josh Schimmer maintains an Outperform rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and raises the price target from $44 to $57.
June 20, 2024 | 2:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group analyst Josh Schimmer maintains an Outperform rating on Longboard Pharmaceuticals and raises the price target from $44 to $57.
The raised price target and maintained Outperform rating by a reputable analyst is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100